Immunovant (IMVT) Share-based Compensation (2019 - 2026)
Immunovant (IMVT) posted Share-based Compensation of -$44.5 million for Q1 2026, down 450.06% on a QoQ basis from $12.7 million in Q4 2025, and down 45518.37% year-over-year from N/an in Q1 2025.
Immunovant (IMVT) Share-based Compensation (2019 - 2026) Analysis & Trends
Immunovant's Share-based Compensation history runs 8 years deep, the most recent figure standing at -$44.5 million for Q1 2026.
- Quarterly Share-based Compensation fell 45518.37% year-over-year to -$44.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $73000.0 (down 25.51% YoY) and the FY2026 annual result came in at $73000.0, down 25.51% from the prior year.
- Share-based Compensation was -$44.5 million for Q1 2026 at Immunovant, down from $12.7 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $18.5 million in Q2 2025 and bottomed at -$44.5 million in Q1 2026.
- A 5-year average of $606117.6 and a median of $8.9 million in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2025 — Share-based Compensation surged 148.63% — and 2026, when it slumped 45518.37%.
- Immunovant's Share-based Compensation stood at $8.9 million in 2022, then advanced by 14.75% to $10.2 million in 2023, then plunged by 355.85% to -$26.1 million in 2024, then jumped by 148.63% to $12.7 million in 2025, then sank by 450.06% to -$44.5 million in 2026.
- Business Quant data shows IMVT's Share-based Compensation at -$44.5 million in Q1 2026, $12.7 million in Q4 2025, and $13.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Immunovant | 7.18 Bn | 7.18 Bn | - | -44.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.51 Mn |
| Mar 31, 2026 | -44.51 Mn |
| Dec 31, 2025 | 12.72 Mn |
| Dec 31, 2025 | 12.72 Mn |
| Sep 30, 2025 | 13.36 Mn |
| Sep 30, 2025 | 13.36 Mn |
| Jun 30, 2025 | 18.51 Mn |
| Jun 30, 2025 | 18.51 Mn |
| Mar 31, 2025 | 98,000.00 |
| Mar 31, 2025 | 98,000.00 |
| Dec 31, 2024 | -26.15 Mn |
| Dec 31, 2024 | -26.15 Mn |
| Sep 30, 2024 | 12.69 Mn |
| Sep 30, 2024 | 12.69 Mn |
| Jun 30, 2024 | 13.46 Mn |
| Jun 30, 2024 | 13.46 Mn |
| Mar 31, 2024 | -31.35 Mn |
| Mar 31, 2024 | -31.35 Mn |
| Dec 31, 2023 | 10.22 Mn |
| Dec 31, 2023 | 10.22 Mn |